Inclusion complexes of optically active 1,4-dihydropyridines with methyl-. beta.-cyclodextrin

摘要

Novel inclusion complexes of racemic 1,4-dihydropyridines and enantiomers thereof of the formula ##STR1## wherein R represents a phenyl group, substituted with nitro, trifluoromethyl, difluoromethoxy group or with one or two halo atoms (especially chlorine),PPR.sub. 1 and R.sub.2, if the same, represent methyl groups and if one of them has the meaning of a 2-aminoethoxymethyl or cyano group, the other represents a methyl group,PPR.sub.3 and R.sub.4, if different, stand each time for a hydrogen, linear or branched C.sub.1 -C. sub.6 -alkyl, 2-methoxyethyl, 1-(phenylmethyl)-3-piperidinylphenyl, styryl, furyl, piperidino, 4-diphenylmethyl-1-piperazinylethyl, 5-phenyl- 3-pirazolyloxy, 1-phenyl-methyl-3-pyrrolidinyl group or a group of the formula ##STR2## or, if the same, stand each time C.sub.1 -C.sub.4 alkyl group, and of acid addition salts thereof with methyl--cyclodextrin, hydroxy-ethyl--cyclodextrin or hydroxypropyl--cyclodextrin, with the exception of inclusion complexes of racemic dihydropyridines with HP--CD, or, in case of amlodipine and enantiomeric nicardipine, also with -cyclodextrin, are disclosed.PPWhilst inclusion complexes of racemic dihydropyridines with the cites cyclodextrins are prepared in a well-known manner disclosed in the literature, enantiomerically pure dihydropyridines and inclusion complexes thereof with cyclodextrins are prepared in a novel way by means of preparative column chromatography.PPThe invention also relates to a pharmaceutical formulation containing novel inclusion complexes and to the use thereof as calcium antagonists for the treatment of hypertension, angina pectoris and cerebrovascular disorders.